Lampire Biological Labs

Executive Summary

Lampire Biological Labs is a privately held biotechnology company founded in 1977 and headquartered in Pipersville, Pennsylvania. The company specializes in advanced monoclonal antibody screening services, offering comprehensive characterization of antibody candidates to accelerate drug discovery and development. Their platform provides high-resolution, data-driven insights including target binding, kinetic profiling, and epitope binning, enabling clients to identify high-affinity, functionally relevant monoclonal antibodies. Lampire operates in the competitive antibodies market, serving biopharmaceutical companies seeking to streamline antibody development. As a private firm with no disclosed funding rounds or valuation, Lampire leverages its decades-long expertise and proprietary technologies to maintain a niche position in the antibody discovery services space.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Monoclonal Screening Platform70% success
• Q4 2026Strategic Partnership with Major Biopharma60% success
• Q1 2027Expansion of Service Offerings into Bispecific Antibodies65% success